dc.contributor.author | Rulli, Nestor E. | |
dc.contributor.author | Suhrbier, Andreas | |
dc.contributor.author | Hueston, Linda | |
dc.contributor.author | Heise, Mark T. | |
dc.contributor.author | Tupanceska, Daniela | |
dc.contributor.author | Zaid, Ali | |
dc.contributor.author | Wilmes, Anja | |
dc.contributor.author | Gilmore, Kerry | |
dc.contributor.author | Lidbury, Brett A. | |
dc.contributor.author | Mahalingam, Surendran | |
dc.date.accessioned | 2018-12-02T23:12:32Z | |
dc.date.available | 2018-12-02T23:12:32Z | |
dc.date.issued | 2005 | |
dc.date.modified | 2014-04-14T23:39:51Z | |
dc.identifier.issn | 01637258 | |
dc.identifier.doi | 10.1016/j.pharmthera.2005.03.006 | |
dc.identifier.uri | http://hdl.handle.net/10072/58387 | |
dc.description.abstract | Ross River virus (RRV) is a mosquito-borne alphavirus indigenous to Australia and the Western Pacific region and is responsible for several thousand cases of human RRV disease (RRVD) per annum. The disease primarily involves polyarthritis/arthralgia, with many patients also presenting with rash, myalgia, fever, and/or lethargy. The symptoms can be debilitating at onset, but they usually resolve within 3-6 months. Recent insights into the RRV-host relationship, associated pathology, and molecular biology of infection have generated a number of potential avenues for improved treatment. Although vaccine development has been proposed, the small market size and potential for antibody-dependent enhancement (ADE) of disease make this approach unattractive. Recent insights into the molecular basis of RRV-ADE and the virus's ability to manipulate host inflammatory and immune responses create potential new opportunities for therapeutic invention. Such interventions should overcome virus-induced dysregulation of protective host responses to promote viral clearance and/or ameliorate inflammatory immunopathology. | |
dc.description.peerreviewed | Yes | |
dc.description.publicationstatus | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.publisher.place | United States | |
dc.relation.ispartofstudentpublication | N | |
dc.relation.ispartofpagefrom | 329 | |
dc.relation.ispartofpageto | 342 | |
dc.relation.ispartofissue | 3 | |
dc.relation.ispartofjournal | Pharmacology & Therapeutics | |
dc.relation.ispartofvolume | 107 | |
dc.rights.retention | Y | |
dc.subject.fieldofresearch | Medical Virology | |
dc.subject.fieldofresearch | Pharmacology and Pharmaceutical Sciences | |
dc.subject.fieldofresearchcode | 110804 | |
dc.subject.fieldofresearchcode | 1115 | |
dc.title | Ross River virus: Molecular and cellular aspects of disease pathogenesis | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dc.type.code | C - Journal Articles | |
gro.date.issued | 2005 | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Rulli, Nestor | |
gro.griffith.author | Zaid, Ali | |
gro.griffith.author | Mahalingam, Suresh | |